Next Article in Journal
Lovastatin Differentially Regulates α7 and α4 Neuronal Nicotinic Acetylcholine Receptor Levels in Rat Hippocampal Neurons
Next Article in Special Issue
In Silico and In Vitro Analysis of Major Cannabis-Derived Compounds as Fatty Acid Amide Hydrolase Inhibitors
Previous Article in Journal
The Effect of Partial Corticotomy on the Rate of Maxillary Canine Retraction: Clinical and Radiographic Study
Previous Article in Special Issue
Cannabidiol Determination on Peripheral Capillary Blood Using a Microsampling Method and Ultra-High-Performance Liquid Chromatography Tandem Mass Spectrometry with On-Line Sample Preparation
Review

Chronological Review and Rational and Future Prospects of Cannabis-Based Drug Development

1
Institute of Plant Science, Agriculture Research Organization, Volcani Center, Rishon LeZion 7528809, Israel
2
Department of Urology, Sheba Medical Center, Ramat Gan 5262000, Israel
3
Consultant Patrick Poulin Inc., Québec City, QC G1V 0A6, Canada
4
School of Public Health, Université de Montréal, Montréal, QC H3T 1J4, Canada
*
Author to whom correspondence should be addressed.
Academic Editor: Francesco Paolo Busardò
Molecules 2020, 25(20), 4821; https://doi.org/10.3390/molecules25204821
Received: 30 August 2020 / Revised: 7 October 2020 / Accepted: 16 October 2020 / Published: 20 October 2020
(This article belongs to the Special Issue Pharmaceutical Drugs Based on Cannabis)
Despite the surge in cannabis chemistry research and its biological and medical activity, only a few cannabis-based pharmaceutical-grade drugs have been developed and marketed to date. Not many of these drugs are Food and Drug Administration (FDA)-approved, and some are still going through regulation processes. Active compounds including cannabinergic compounds (i.e., molecules targeted to modulate the endocannabinoid system) or phytocannabinoid analogues (cannabinoids produced by the plant) may be developed into single-molecule drugs. However, since in many cases treatment with whole-plant extract (whether as a solvent extraction, galenic preparation, or crude oil) is preferred over treatment with a single purified molecule, some more recently developed cannabis-derived drugs contain several molecules. Different combinations of active plant ingredients (API) from cannabis with proven synergies may be identified and developed as drugs to treat different medical conditions. However, possible negative effects between cannabis compounds should also be considered, as well as the effect of the cannabis treatment on the endocannabinoid system. FDA registration of single, few, or multiple molecules as drugs is a challenging process, and certain considerations that should be reviewed in this process, including issues of drug–drug interactions, are also discussed here. View Full-Text
Keywords: cannabis; cannabinergic; drug; FDA-approved; medical conditions; pharmaceutical-grade; phytocannabinoid cannabis; cannabinergic; drug; FDA-approved; medical conditions; pharmaceutical-grade; phytocannabinoid
Show Figures

Figure 1

MDPI and ACS Style

Namdar, D.; Anis, O.; Poulin, P.; Koltai, H. Chronological Review and Rational and Future Prospects of Cannabis-Based Drug Development. Molecules 2020, 25, 4821. https://doi.org/10.3390/molecules25204821

AMA Style

Namdar D, Anis O, Poulin P, Koltai H. Chronological Review and Rational and Future Prospects of Cannabis-Based Drug Development. Molecules. 2020; 25(20):4821. https://doi.org/10.3390/molecules25204821

Chicago/Turabian Style

Namdar, Dvora, Omer Anis, Patrick Poulin, and Hinanit Koltai. 2020. "Chronological Review and Rational and Future Prospects of Cannabis-Based Drug Development" Molecules 25, no. 20: 4821. https://doi.org/10.3390/molecules25204821

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop